Ertapenem Sodium is a broad-spectrum, β-lactam, carbapenem that interferes with peptidoglycan synthesis. Ertapenem has been commercially available since 2001 and is marked by Merck. The compound is commonly used in antimicrobial susceptibility testing.
Ertapenem Sodium is freely soluble in water but practically insoluble in ethanol.
We also offer:
- Ertapenem Sodium, EvoPure® (E008)
|Mechanism of Action||β-lactams interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBPs are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues, providing additional strength to the cell wall. Ertapanem binds to PBP 2 and PBP 3. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to β-lactams is commonly due to cells containing plasmid-encoded β-lactamases. Erapenem is resistant to hydrolysis by a variety of β-lactamases, including penicillinases, cephalosporinases and extended-spectrum β-lactamases.|
|Spectrum||Ertapenem Sodium has broad-spectrum activity targeting a wide spectrum of aerobic and anaerobic Gram-positive and Gram-negative bacteria.|
|Microbiology Applications||Ertapenem Sodium is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.
Representative MIC values include:
Staphylococcus aureus: 0.12 µg/mL – >16 µg/mL
It is active against cephalosporin-resistant enteric organisms producing Extended-Spectrum Beta-Lactamases (ESBLs) and penicillin-resistant Streptococcus pneumoniae. It has restricted activity against nosocomial pathogens including Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci.
|Molecular Formula||C22H24N3O7S . Na|
Cunha BA (2002) Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (Barc) 38(3):195-213 PMID 12532175
Hammond ML (2004) Ertapenem: A group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother 53(2):7-9 PMID 15150178
Pitout JD, Sanders CC, Sanders WE (1997) Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. Am. J. Med. 103:51
Williams JM (2005) Practical synthesis of the new carbapenem antibiotic Ertapenem Sodium. J. Org. Chem. 70(190):7479–7487 PMID 16149774